Additionally, Zepbound (tirzepatide), a dual-action GIP/GLP-1 receptor agonist, targets two hormones to enhance weight loss
Weight loss in the ten-to-twenty percent range is linked to diabetes remission, improvement in fatty liver, less sleep apnea, lower blood pressure, and, in large cardiovascular trials, fewer heart attacks, strokes, and cardiovascular deaths
The best approach for variable income: Build a medication fund during high-income months
Get straight-talking tips, science-backed insights, and everything you need to fuel your health, feed your gut, and power your brainwithout the fluff
The human body naturally produces some L-carnitine, but factors such as aging, dietary restrictions, or high levels of physical activity can reduce its availability
Diabetes Care 36:29452951 Fonseca VA, Alvarado-Ruiz R, Raccah D et al (2012) Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)